BTG2019
March 15-17, 2019
Shangri-la Hotel
Fuzhou, China
APHCON HOME
APHCON: Asia Pacific Hematology Consortium
Comprising of hematologist/ oncologists from 28 different countries, APHCON is the necessary platform that unites the physicians with the global network as well as allows for true collaborations that lead to improved patient care.
Mission Statement:
Advance field of hematology oncology through continued education, collaboration and fostering innovations.
Comprising of hematologist/ oncologists from 28 different countries, APHCON is the necessary platform that unites the physicians with the global network as well as allows for true collaborations that lead to improved patient care.
Mission Statement:
Advance field of hematology oncology through continued education, collaboration and fostering innovations.
APHCON President
SURAPOL ISSARAGRISIL, MD, FRCP, FACP, FRCPA, FRCPath
- Professor of Medicine, Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
- Director, Chulabhorn Bone Marrow Transplant Center
- Director, Siriraj Center of Excellence for Stem Cell Research
- Fellow of Royal Institute (Thailand), Academy of Science
- President of the Thai Society for Stem Cell Research
APHCON Executive Director
XIAO JUN HUANG, MD, PhD
- Dr Huang is Professor of Medicine and Hematology; Chairman, Peking University Institute of Hematology. Director and Chief Physician, Department of Hematology, Peking University People's Hospital. Beijing, China
Dr Huang was the first president of APHCON and is also holds several prestigious offices:
President , Chinese Society of Hematology,CMA
Chairman, Chinese Association of Hematologists,CMDA
Chairman, Chinese Hematopoietic Stem Cell Transplantation Association, CMA
Vice Chairman, Chinese Pathophysiological Association of Experimental Hematology
Member,National Natural Science Foundation of China, the Expert Evaluation Team of the Ministry of Medicine and Science.
Director, Chinese Medical Association Beijing Hematology Branch
Leadership: As the Head of the Association of Chinese Hematologists, 5 years ago Dr Huang established a platform of education for professional standardization to junior hematologists in Mainland China. It consists of series of conference that covers around 20 cities each year in China.
APHCON Commitment: To unite the practicing hematologists of participating nations and provide educational opportunities to the younger generation.
APHCON Mobile Educational Platform Partner: MDRing
MDRing™ is founded by physicians and is a global education network dedicated to communicating cutting edge medical science and improving patient outcomes worldwide with a mobile first platform. MDRing™ allows for individual physician to create a permanent profile, participate in answering multiple choice questions and get immediate feedback in form of real time data visualization of the correct answer as well as their individual standing among their peers.
As a result of this collaboration, we have published 3 manuscripts with the 3 manuscripts in preparation and pending submission.
www.mdring.com
As a result of this collaboration, we have published 3 manuscripts with the 3 manuscripts in preparation and pending submission.
www.mdring.com
July 2015: APHCON published first collaborative study using data obtained from BTG2015, Beijing China. There will be 6 additional papers that will be published.
July 2015: Winners of MDRing challenge at Chinese Association of Hematology Conference, Shenyang, China
JAN 9, 2015: The University of Texas MD Anderson Cancer Center was presented the People’s Republic of China International Science and Technology Cooperation Award at a ceremony held Jan. 9 at Beijing’s Great Hall of the People.
The event, attended by Chinese President Xi Jinping, Premier Li Keqiang, and Vice Premier Liu Yandong, recognized MD Anderson’s many international ties to sister institutions in China with which it shares collaborative programs in training, education and patient care. The award is granted through the Chinese State Council to foreign scientists, science and technology engineers and managers, or organizations that have “made important contributions to China’s bilateral or multilateral scientific and technological cooperation.” Oliver Bogler, Ph.D., senior vice president for academic affairs accepted the award on behalf of MD Anderson. Ta-Jen Liu, Ph.D., project director of global academic programs, also attended the ceremony. “Cancer is a significant challenge worldwide,” said Bogler. “Every country has a unique spectrum of cancers, influenced by factors such as population and environment, and collaborating to study these cancers is critical to making progress. China in particular offers tremendous opportunities for saving lives through joint cancer research with top scientists and the government’s commitment to fighting cancer.” Bogler added that collaborations with Chinese partners have been productive in areas such as cancer screening, liver and lung cancer treatment, and cooperation in clinical trials and basic research studies. “It is increasingly important to share information and create ties that help all nations in our collective fight against cancer,” said Ron DePinho, M.D., president of MD Anderson. “Receiving this coveted award from China is an honor for our institution and one that speaks to our commitment to collaboration, here at home and across the globe.” MD Anderson was nominated for the award by its sister institution, Sun Yat-sen University Cancer Center in Guangzhou. Other MD Anderson sister institutions include the Chinese Academy of Medical Sciences Cancer Institute and Hospital, Beijing; Tianjin Medical University Cancer Institute and Hospital; Fudan University Shanghai Cancer Center; and the Sir YK Pao Centre for Cancer, Chinese University of Hong Kong. SIRIRAJ and BANGKOK HOSPITAL join
|